GSK 923295
Alternative Names: GSK-923295; GSK-923295ALatest Information Update: 05 Nov 2023
At a glance
- Originator Cytokinetics
- Developer GSK
- Class Antineoplastics; Small molecules
- Mechanism of Action Centromere protein E inhibitors; Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 19 Nov 2009 Drug interactions data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 19 Nov 2009 Pharmacodynamics data from in vitro studies in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,
- 01 Jun 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)